Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1989 1
1996 2
1997 2
1998 2
1999 3
2000 1
2001 3
2002 6
2003 4
2004 3
2005 4
2006 5
2007 35
2008 110
2009 138
2010 259
2011 385
2012 488
2013 601
2014 838
2015 987
2016 1084
2017 1317
2018 1489
2019 1664
2020 2105
2021 2403
2022 2450
2023 2515
2024 2183
2025 3

Text availability

Article attribute

Article type

Publication date

Search Results

18,925 results

Results by year

Filters applied: . Clear all
Page 1
Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L, Duan JJ, Bian XW, Yu SC. Yin L, et al. Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5. Breast Cancer Res. 2020. PMID: 32517735 Free PMC article. Review.
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include hi …
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express es …
Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy.
Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM. Yang F, et al. Cell Metab. 2023 Jan 3;35(1):84-100.e8. doi: 10.1016/j.cmet.2022.09.021. Epub 2022 Oct 17. Cell Metab. 2023. PMID: 36257316 Free article.
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metabolic pathways in regulating ferroptosis will provide new insights into TNBC therapeutic strategies. ...
Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of m …
Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Li Y, et al. J Hematol Oncol. 2022 Aug 29;15(1):121. doi: 10.1186/s13045-022-01341-0. J Hematol Oncol. 2022. PMID: 36038913 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. ...TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Hence, …
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a po …
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest rates of recurrence and mortality. ...Furthermore, advances in drug development have led to the approval of antibody-drug conjugates that a …
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the highest …
Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies.
Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW, Park J, Jeang JW, Kang SC. Karim AM, et al. Biochem Pharmacol. 2023 Jun;212:115545. doi: 10.1016/j.bcp.2023.115545. Epub 2023 Apr 11. Biochem Pharmacol. 2023. PMID: 37044296 Review.
Long-standing scarcity of efficacious treatments and tumor heterogeneity have contributed to triple-negative breast cancer (TNBC), a subtype with a poor prognosis and aggressive behavior that accounts for 10-15% of all new cases of breast …
Long-standing scarcity of efficacious treatments and tumor heterogeneity have contributed to triple-negative breast …
Role of Immunotherapy in Triple-Negative Breast Cancer.
Keenan TE, Tolaney SM. Keenan TE, et al. J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. J Natl Compr Canc Netw. 2020. PMID: 32259782 Review.
However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast cancer (TNBC), which has several key characteristics that enhance ICI responses. ...
However, the single-agent efficacy of ICIs in breast cancer is low, including in triple-negative breast …
Advances in immunotherapy for triple-negative breast cancer.
Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. Liu Y, et al. Mol Cancer. 2023 Sep 2;22(1):145. doi: 10.1186/s12943-023-01850-7. Mol Cancer. 2023. PMID: 37660039 Free PMC article. Review.
This offers the possibility of reducing mortality in triple-negative breast cancer (TNBC). MAIN BODY: Immunotherapy approaches for TNBC have been diversified in recent years, with breakthroughs in the treatment of this entity. ...This review hig …
This offers the possibility of reducing mortality in triple-negative breast cancer (TNBC). MAIN BODY: Immunother …
Triple-negative breast cancer: recent treatment advances.
Bergin ART, Loi S. Bergin ART, et al. F1000Res. 2019 Aug 2;8:F1000 Faculty Rev-1342. doi: 10.12688/f1000research.18888.1. eCollection 2019. F1000Res. 2019. PMID: 31448088 Free PMC article. Review.
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affect younger women, metastasise early despite optimal adjuvant treatment and carry a poor prognosis. Neoadjuvant therapy has focu …
Triple-negative breast cancer (TNBC) is a breast cancer subtype renowned for its capacity to affec …
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
Shiao SL, Gouin KH 3rd, Ing N, Ho A, Basho R, Shah A, Mebane RH, Zitser D, Martinez A, Mevises NY, Ben-Cheikh B, Henson R, Mita M, McAndrew P, Karlan S, Giuliano A, Chung A, Amersi F, Dang C, Richardson H, Shon W, Dadmanesh F, Burnison M, Mirhadi A, Zumsteg ZS, Choi R, Davis M, Lee J, Rollins D, Martin C, Khameneh NH, McArthur H, Knott SRV. Shiao SL, et al. Cancer Cell. 2024 Jan 8;42(1):70-84.e8. doi: 10.1016/j.ccell.2023.12.012. Cancer Cell. 2024. PMID: 38194915
Here we employ single-cell transcriptomics and spatial proteomics to profile triple negative breast cancer biopsies taken at baseline, after one cycle of pembrolizumab, and after a second cycle of pembrolizumab given with radiotherapy. ...The other res …
Here we employ single-cell transcriptomics and spatial proteomics to profile triple negative breast cancer biops …
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Garrido-Castro AC, Lin NU, Polyak K. Garrido-Castro AC, et al. Cancer Discov. 2019 Feb;9(2):176-198. doi: 10.1158/2159-8290.CD-18-1177. Epub 2019 Jan 24. Cancer Discov. 2019. PMID: 30679171 Free PMC article. Review.
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. ...SIGNIFICANCE: TNBC is characterized by higher rates of relapse, greater metastatic potential, and shorter overall survival compared with …
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat. …
18,925 results
You have reached the last available page of results. Please see the User Guide for more information.